Sugi Predict

Sugi Predict / Compounds / SCHEMBL30327366

SCHEMBL30327366

SCHEMBL30327366

CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CO)C(C)C)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ RAMP3 O60896 6/20 0.48
▸ CALCR P30988 6/20 0.48
▸ EPHA2 P29317 2/20 0.48
▸ NPY2R P49146 7/20 0.47
▸ NPY4R P50391 7/20 0.47
▸ NPY5R Q15761 7/20 0.47
▸ NPY1R P25929 5/20 0.47
▸ CXCR4 P61073 2/20 0.47
▸ C5AR1 P21730 1/20 0.46
▸ NMUR2 Q9GZQ4 1/20 0.46
▸ NMUR1 Q9HB89 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29636368 0.90 EPHA2 (0.53) RAMP3CALCREPHA2CXCR4C5AR1
SCHEMBL29427923 0.89 EPHA2 (0.49) RAMP3CALCREPHA2NPY2RNPY4R
SCHEMBL30974524 0.88 NPY2R (0.52) RAMP3CALCREPHA2NPY2RNPY4R
SCHEMBL30974426 0.87 RAMP3 (0.52) RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL30974190 0.86 MAPK8 (0.48) RAMP3CALCREPHA2NPY2RNPY4R
SCHEMBL31462049 0.85 NPY2R (0.46) EPHA2NPY2RNPY4RNPY5RNPY1R
SCHEMBL31031579 0.85 NPY2R (0.47) RAMP3CALCREPHA2NPY2RNPY4R
SCHEMBL31462085 0.85 NTSR2 (0.47) EPHA2NPY2RNPY4RNPY5RNPY1R
SCHEMBL31031561 0.85 NPY2R (0.52) RAMP3CALCREPHA2NPY2RNPY4R
SCHEMBL30973974 0.84 RAMP3 (0.53) RAMP3CALCREPHA2C5AR1NMUR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034197-A1 Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases BETAVIVE LTD. (IL) 2026-02-05 — — US disclosed
US-12447198-B2 Peptides and fragments for treating diabetes and associated metabolic diseases BETAVIVE LTD. (IL) 2025-10-21 — — US disclosed
US-20230120635-A1 Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases BETAVIVE LTD. (IL) 2023-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230120635-A1 Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases IAPP, IGFBP2, IGFBP1 RAMP3 2356/4885CALCR 621/4885EPHA2 1995/4885
US-12447198-B2 Peptides and fragments for treating diabetes and associated metabolic diseases IAPP, IGFBP2, IGFBP1 RAMP3 2356/4885CALCR 621/4885EPHA2 1995/4885
US-20260034197-A1 Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases IAPP, GLP1R, IGF1R RAMP3 2603/4885CALCR 385/4885EPHA2 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.